The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | Ongoing trials in MCL with practice-changing potential
In this video, Tycel Phillips, MD, City of Hope, Duarte, CA, discusses the ongoing clinical trials with practice-changing potential in the field of mantle cell lymphoma (MCL), highlighting the ongoing MANGROVE study (NCT04002297), which is comparing zanubrutinib plus rituximab to bendamustine plus rituximab. He also mentions the GLOBRYTE study (NCT06084936), which evaluates the bispecific antibody glofitamab versus standard treatments in the relapsed/refractory (R/R) setting, as well as several ongoing studies assessing novel CAR T-cell products. This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Ongoing right now, as far as practice-changing studies, we will have the MANGROVE study, which is Zanubrutinib and Rituximab versus BR, that we’ll hopefully be reading out very shortly. In this clinical protocol, obviously, it’ll be evaluating a truly chemo-free regimen versus BR. Just some context, obviously, we have the British study, ENRICH, that looked at ibrutinib and Rituximab versus BR or R-CHOP, which showed equivalency to BR, so it’ll be very curious to see how this study reads out with the caveat that MANGROVE did not allow any Rituximab maintenance for the BR arm, so that may play some part in the progression-free survival...
Ongoing right now, as far as practice-changing studies, we will have the MANGROVE study, which is Zanubrutinib and Rituximab versus BR, that we’ll hopefully be reading out very shortly. In this clinical protocol, obviously, it’ll be evaluating a truly chemo-free regimen versus BR. Just some context, obviously, we have the British study, ENRICH, that looked at ibrutinib and Rituximab versus BR or R-CHOP, which showed equivalency to BR, so it’ll be very curious to see how this study reads out with the caveat that MANGROVE did not allow any Rituximab maintenance for the BR arm, so that may play some part in the progression-free survival.
In the relapsed/refractory setting, there’s still the ongoing GLOBRYTE study, which is looking at the bispecific antibody Glofitamab versus standard of choice, which is R-squared, lenalidomide-Rituximab, or Bendamustine-Rituximab in patients who progress after BTK inhibitor.
Lastly, there are several ongoing studies looking at some novel CAR T-cell products within the mantle cell lymphoma space, and given unfortunately, we still are not necessarily curing these patients, it’ll be very important to get some more sort of treatment options into this field to help salvage some of these patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
